Targeted Therapy
Why is targeted therapy a focus theme in 2020?
What is driving the resurgence of targeted therapies in oncology?
As tumor genomic profiling is becoming more common, investment in the capabilities to develop precision medicines against new targets and mechanisms of resistance should strengthen oncology strategy. Significant acquisitions and promising data fueled investor sentiment in 2019, and we expect continued focus on targeted therapy into 2020.
Increasingly robust understanding of the genetic mutations driving certain cancers partially de-risks the development of targeted oncology, which appeals to many investors and potential acquirers. Moreover, there will be catalysts in 2020, including potential approval and launch of a new drug in Triple Negative Breast Cancer, which alone could exceed $1 billion in sales over the next few years, in our view.
What we’re watching:
- Capmatinib
- KRAS
- Sacituzumab
- Selpercatinib
- M&A
$100B
Expected overall sales of targeted therapies in 2023
$2.8B
Estimated TAM for kras g12c inhibitors in 2022
2x
Average overall response rate of patients treated with targeted therapies in 1L, 1L ALK+, 1L EGFR+, 1L ROS+ and 1L RET+ Settings vs. Chemo or Immuno Therapies
25%
Percentage of human cancers activated by ras mutation
